The Single-Domain Antibody Platforms Market To Enter The “Decisive Mode” BetweenPosted by Ashish on April 14th, 2021 Monoclonal antibodies are highly efficient as therapeutics against viral infections, immune diseases, and cancer. However, they are large in size and unable to access some epitopes, besides the production cost being high. Hence, single-domain antibodies (sdAbs) is an alternative for monoclonal due to larger number of accessible epitopes, smaller size, relatively low production costs, and potent inhibitors against immune and viral diseases. Currently, single-domain antibodies are being developed against a number of viruses, including influenza viruses, HIV, hepatitis C virus (HCV), enteric viruses, and respiratory syncytial virus (RSV). Technological advancements in single-domain antibody platforms such as production of bispecific and multi-specific antibodies to target particular antigens during therapeutic developments are some other factors that will boost the growth of the single-domain antibody platforms market. Planning Forward? Access Sample Of Single-Domain Antibody Platforms Market Report! https://www.persistencemarketresearch.co/samples/28351 Companies covered in Single Domain Antibody Platforms Market Report
Like it? Share it!More by this author |